Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent

Table 3

Univariate and multivariate analysis of progression free survival in patients with colorectal cancer, treated with melphalan or mitomycin-C as a HIPEC agent.

		Univariate		Multivariate
Characteristics	N	Medial PFS months; (95% CI)	p-value	HR; (95% CI)	p-value
Agent			0.05		0.17
Melphalan	18	10 (6-13)		1.62 (0.81-3.27)
Mitomycin-C	28	24 (9-39)
Age			0.36		0.89
≤53 years	32	13 (3-23)
>53years	14	11 (9-11)		0.95 (0.47-1.96)
CC score			0.11		0.67
CC-0	38	13 (3-23)
CC-1	8	12 (10-16)		1.22 (0.49-3.08)
PCI			<0.001		<0.001
≤20	25	28 (18-38)
>20	20	10 (4-16)		4.52 (2.05-9.95)
LN status			0.64		0.97
LN metastases	19	10 (9-12)		1.01 (0.5-2.07)
no LN metastases	23	12 (9-15)

HR: hazard ratio; PCI: peritoneal carcinomatosis index; LN: lymph nodes; PFS: progression-free survival; was used as reference in multivariate analysis; Median age of all patients was 53 years.